Projects per year
Personal profile
Personal profile
Dr. Teh is a professor and vice chair of the Department of Radiation Oncology at Houston Methodist Hospital and Weill Medical School of Cornell. Dr. Teh has contributed significantly to the field of radiation oncology – encompassing radiotherapy technology, radiation physics, molecular radiobiology and the translation of advances in these areas to clinical use. He has been instrumental in pioneering new technology in radiation oncology including APBI (accelerated partial breast irradiation), IMRT (intensity-modulated radiation therapy), IGRT (image-guided radiation therapy), SBRT (stereotactic body radiation therapy), SRS (stereotactic radiosurgery), brachytherapy as well as combined radiotherapy and gene therapy. Dr. Teh treated the first breast cancer patient in Houston with multi-lumen catheter (Contura) high dose rate brachytherapy for partial breast irradiation. This is a short course of five days irradiation, as compared to the conventional six weeks irradiation for breast cancer. Partial breast irradiation is a novel approach to spare more normal tissues.
Dr. Teh earned his medical degree from the University of Queensland in Queensland, Australia. He completed his Radiation Oncology residency, training and fellowship in IMRT at the Baylor College of Medicine in Houston, Texas. Dr. Teh is active in ASTRO (American Society of Therapeutic Radiology and Oncology), RSNA (Radiological Society of North America and ARS (American Radium Society). He is the principal investigator for RTOG (Radiation Therapy Oncology Group) at Houston Methodist Hospital. Dr. Teh has published more than 100 peer-reviewed articles on topics such as IMRT for breast cancer, editorials, 15 book chapters and a textbook on PET-CT in radiotherapy. He plays an important role in breast cancer patient care, clinical research and the education of residents and students.
Research interests
Dr. Teh’s research focuses on the treatment of genito-urinary malignancies and unlocking the myth of radio-resistance in cancers especially renal cell carcinoma. Other research interests include Intensity modulated radiation therapy (IMRT) for prostate cancer, head and neck cancer, central nervous system tumor, pediatric cancer and breast cancer, stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT), stereotactic radiation therapy (SRT) and image-guided radiation therapy (IGRT), brachytherapy for prostate cancer, breast cancer and endobronchial tumors, SRS and SBRT for primary and metastatic renal cell carcinoma as well as hepatocellular carcinoma, the role of combined radiotherapy and gene therapy for cancers including prostate cancer, renal cell carcinoma, bladder cancer, pancreatic cancer, glioblastoma multiforme, cervical cancer and head and neck cancer, combining targeted therapy (AKT-inhibitor, mTOR inhibitor, tyrosine kinase inhibitor) with radiotherapy for cancer treatment, and combining oncolytic virus with radiotherapy in overcoming radio-resistant tumors in oncology.
Education/Academic qualification
Radiation Oncology, Clinical Fellowship, Baylor College of Medicine
Jul 1 1998 → Jun 30 1999
Award Date: Jun 30 1999
Radiation Oncology, Residency, Baylor College of Medicine
Jul 1 1994 → Jun 30 1998
Award Date: Jun 30 1998
MD, University of Queensland
… → Dec 31 1990
Award Date: Dec 31 1990
Research Area Keywords
- Cancer
- Imaging & Radiology
Free-text keywords
- Cancer stem cells
- Radio-resistance
- Prostate Movement study
- Post-prostatectomy IMRT
- Gene expression profiling in cancer
- Proteomics in oncology
Fingerprint
- 1 Similar Profiles
Network
-
A Phase II Clinical tRial of neoADjuVant sAsanlimab and stereotaCtiC body radIatioN thErapy as an in situ vaccine for cisplatin-ineligible Muscle Invasive Bladder Cancer (RAD VACCINE MIBC)
Satkunasivam, R., Chen, S., Esnaola, N. F., Farach, A. M., Teh, B. S. & Zhang, J.
1/20/22 → …
Project: Clinical Trial
-
Phase I-II Study Evaluating HSV-tk + Valacyclovir Gene Therapy
Baskin, D. S., Butler, E. B. & Teh, B. S.
1/15/18 → …
Project: Clinical Trial
-
21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy
Chevli, N., Haque, W., Tran, K. T., Farach, A. M., Schwartz, M. R., Hatch, S. S., Butler, E. B. & Teh, B. S., Sep 2022, In: Radiotherapy and Oncology. 174, p. 37-43 7 p.Research output: Contribution to journal › Article › peer-review
-
A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: The RAD VACCINE MIBC trial
Satkunasivam, R., Lim, K., Teh, B. S., Guzman, J., Zhang, J., Farach, A., Chen, S. H., Wallis, C. J. D., Efstathiou, E., Esnaola, N. F. & Sonpavde, G. P., Aug 2022, In: Future Oncology. 18, 25, p. 2771-2781 11 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Clinical factors and association with treatment modalities in patients with breast cancer and brain metastases who develop leptomeningeal metastases
Puri, A., Mylavarapu, C., Xu, J., Patel, T. A., S.Teh, B., Tremont-Lukats, I., Chang, J. C. & Niravath, P., Jun 2022, In: Breast Cancer Research and Treatment. 193, 3, p. 613-623 11 p.Research output: Contribution to journal › Article › peer-review
-
Contemporary trends in management of uveal melanoma
Chevli, N., Zuhour, R. J., Messer, J. A., Haque, W., Schefler, A. C., Bernicker, E. H., Chevez-Barrios, P., Farach, A. M., Butler, E. B. & Teh, B. S., 2022, In: Journal of Contemporary Brachytherapy. 14, 2, p. 123-129 7 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Neoadjuvant Chemotherapy for Metaplastic Breast Cancer: Response Rates, Management, and Outcomes
Haque, W., Verma, V., Schwartz, M. R., Lim, B., Mangalampalli, N., Butler, E. B. & Teh, B. S., Jul 2022, In: Clinical Breast Cancer. 22, 5, p. e691-e699Research output: Contribution to journal › Article › peer-review
3 Scopus citations